Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: A pilot study

Circulation

Volumn 96, Issue 3, 1997, Pages 769-777

  Yusuf, Salim ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Angina; Heparin; Hirudin; Myocardial infarction

Indexed keywords

HEPARIN; LEPIRUDIN;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAM; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PARTIAL THROMBOPLASTIN TIME; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; ST SEGMENT ELEVATION; STROKE; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 0343580449     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.96.3.769     Document Type: Article

References (18)

1. Fuster V, Badimon L, Cohen M, Ambrose JA, Badimon JJ, Cheseboro JH. Insights into the pathogenesis of acute ischemic syndromes. Circulation. 1988;77:1213-1220.
2. Yusuf S, Sleight P, Held P, MacMahon S. Routine medical management of acute myocardial infarction: lessons from overviews of recent randomized controlled trials. Circulation. 1990;82(suppl II): II-117-II-134.
3. The TIMI IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: results of the TIMI IIIB Trial. Circulation. 1994;89:1545-1556.
4. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy, 1: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81-106.
5. Cairns JA, Gent M, Singer J, Finnie KJ, Froggatt GM, Holder D, Jablonsky G, Kostuk WJ, Melendez LJ, Myers MG. Aspirin, sulfin-pyrazone, or both in unstable angina: results of a Canadian Multicentre Trial. N Engl J Med. 1985;313:1369-1375.
6. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease: unstable angina, heart failure, primary prevention with aspirin, and risk factor modification. JAMA. 1988;2601:2259-2263.
7. Theroux P, Ouimet H, McCans J, Latour JG, Joly P, Levy G, Pelletier E, Juneau M, Stasiak J, deGuise P. Aspirin, heparin or both to treat unstable angina. N Engl J Med. 1988;319:1105-1111.
8. Fragmin During Instability in Coronary Artery Disease (FRISC) Study Group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet. 1996;347:561-568.
9. Connor C, McCabe C, Henry T, Rogers W, Schweiger M, Gibson R, Anderson J, Williams D, Braunwald E, for the TIMI 5 Investigators. Hirudin reduces reocclusion compared to heparin following thrombolysis in acute myocardial infarction: results of the TIMI 5 trial. J Am Coll Cardiol. 1993;21:136A. Abstract.
10. The Global Use of Strategies to Open Occluded Arteries (GUSTO) IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation. 1994;90:1631-1637.
11. Antman EM, for the TIMI 9A Investigators. Hirudin in acute myocardial infarction: safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. Circulation. 1994;90:1624-1630.
12. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22: 719-748.
13. Cook RJ, Lawless JF, Nadeau C. Robust tests for treatment comparisons based on recurrent event responses. Biometrics. 1996;52: 116-130.
14. Flather M, Pogue J, Weitz J, Morris A, Sussex B, Joyner C, Gill J, Jessel A, Yusuf S. Hirudin (HBW-023) suppresses markers of coagulation more effectively than heparin. Circulation. 1996;94(suppl I):I-696. Abstract.
15. Neuhaus KL, von Essen R, Tebbe U, Jessel A, Heinrichs H, Maurer W, Doring W, Harmjanz D, Kolter V, Kalhammer E, Simon H, Horacek T. Safety observations from the pilot phase of the randomized r-hirudin for improvement of thrombolysis (HIT-III) study. Circulation. 1994;90:1638-1642.
16. Lefkovitz J, Horrigan MC. Is the risk of intracerebral hemorrhage greater with direct thrombin inhibitors than with platelet GP IIb/IIIa antagonists? A meta-analysis of recent clinical trials. Circulation. 1995;92(suppl I):I-80. Abstract.
17. Antman EM, for the TIMI 9B Investigators. Hirudin in acute myocardial infarction: thrombolysis and thrombin inhibition in acute myocardial infarction: (TIMI) 9B Trial. Circulation. 1996;94: 911-921.
18. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med. 1996;335:775-782.